Abstracts tagged "clinical trials and laboratory tests"

Abstract Number: 1527 • 2019 ACR/ARP Annual Meeting
Limited Changes in Hematological Parameters During Tildrakizumab Treatment: Post Hoc Analysis of Data from the Tildrakizumab Psoriasis Clinical Program
Holly Glover ¹, Kristine Kucera ², Alan Mendelsohn³, Jeff Parno ³, Stephen Rozzo ³, Frank Ferritto ⁴ and Renata Block ⁵, ¹Dermatology and Skin Cancer Surgery Center, McKinney, TX, USA, McKinney, TX, ²North Texas Dermatology, Richardson, TX, USA, Richardson, TX, ³Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ⁴Polley Dermatology, Wilson, NC, USA, Wilson, NC, ⁵Pinski Dermatology & Cosmetic Surgery, Chicago, IL, USA, Chicago, IL
Background/Purpose: Tildrakizumab (TIL) is a high-affinity, anti–interleukin‐23p19 monoclonal antibody with demonstrated efficacy for the treatment of chronic plaque psoriasis in a phase 2b (P05495 [NCT01225731])…